Kirin's NESP(R) Long-Acting Erythropoiesis Stimulating Agent Injection Syringe Receives Approval in Japan.Tokyo, Japan, Apr 25, 2007 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Kirin Brewery announced that it received manufacturing and marketing approval for its long-acting erythropoiesis erythropoiesis /eryth·ro·poi·e·sis/ (-poi-e´sis) the formation of erythrocytes.erythropoiet´ic e·ryth·ro·poi·e·sis n. The formation or production of red blood cells. stimulating agent Darbepoetin Alfa, brand name NESP NESP Neuroendocrine Secretory Protein NESP Navy EHF SATCOM Program NESP Nurse Educator Scholarship Program NESP Navy EHF Satellite Program NESP National Environmental Studies Project NESP National Education Supercomputer Program (R) Injection Syringe, on April 18, 2007. NESP(R) is manufactured by partially modifying the amino acid sequence of human erythropoietin (EPO EPO see erythropoietin. EPO Erythropoietin, see there ) and attaching new sugar chains. The addition of the sugar chains endows this recombinant protein with a longer serum half-life and sustained erythropoietic Erythropoietic Referring to the creation of new red blood cells. Mentioned in: Porphyrias erythropoietic emanating from or pertaining to erythropoiesis. activity as compared with conventional recombinant human EPO (rHuEPO) preparations. As a result, NESP(R) has the advantage of less frequent administration as compared with conventional rHuEPO preparations, and excellent efficacy in the treatment of anemia. NESP(R) was developed through a collaborative research effort by Kirin and Amgen Inc. (USA) that was initiated in 1996. The drug was first introduced under the brand name Aranesp(R) in the United States and Australia in May of 2001, and it is currently marketed in more than 40 countries worldwide, including Europe, Canada, Taiwan and Korea. In Japan, clinical studies of NESP(R) were initiated in 2000 in hemodialysis patients, and an application for approval was filed in 2005 for the treatment of renal anemia in patients receiving dialysis. Today, more than 250,000 patients are undergoing dialysis treatment in Japan, and that number continues to rise. Renal anemia is the main complication in these patients, and about 80% are treated with rHuEPO preparations. Kirin began marketing a rHuEPO preparation, brand name ESPO Espo Esperanto ESPO European Sea Ports Organization ESPO Enterprise Solutions Program Office ESPO East Siberia - Pacific Ocean (oil pipeline) (R) INJECTION, for the treatment of renal anemia in 1990, which has contributed greatly to the care of dialysis patients with renal anemia. Kirin hope that the launch of NESP(R) is expected not only to contribute to the treatment of dialysis patients but also to provide various additional benefits such as reducing the burden on the health care provider by virtue of its reduced frequency of administration. Additional clinical studies are being carried out on NESP(R) for the treatment of anemia in patients with chronic kidney disease Chronic kidney disease (CKD), also know as chronic renal disease, is a progressive loss of renal function over a period of months or years through five stages. Each stage is a progression through an abnormally low and progressively worse glomerular filtration rate, which is who are not on dialysis, and for chemotherapy induced anemia in cancer patients. Copyright [c] 2007 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion